Icosavax Inc

NASDAQ ICVX

Data sourced from

and

Download Data

Icosavax Inc Total Assets for the year ending December 31, 2022: USD 238.68 M

Icosavax Inc Total Assets is USD 238.68 M for the year ending December 31, 2022, a -17.02% change year over year. Total Assets is the total value of all assets owned by a company, representing its resources.

Icosavax Inc Total Assets for the year ending December 31, 2021 was USD 287.63 M, a 1,678.78% change year over year.
Icosavax Inc Total Assets for the year ending December 31, 2020 was USD 16.17 M, a -30.57% change year over year.
Icosavax Inc Total Assets for the year ending December 31, 2019 was USD 23.29 M.

NASDAQ: ICVX

Icosavax Inc

CEO	Mr. Adam K. Simpson
IPO Date	July 29, 2021
Location	United States
Headquarters	1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees	60
Sector	Healthcare
Industry	Biotechnology

Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Key trends